Cyclin-dependent kinase inhibitor 1A (CDKN1A) gene promoter (CDKN1A promoter)

The Cyclin-dependent kinase inhibitor 1A (CDKN1A) gene promoter is a critical regulatory DNA sequence that governs the transcription of the p21 protein, a master regulator of the cell cycle and a key mediator of the p53 tumor suppressor pathway (Source: NIH, GeneCards). p21 inhibits cyclin-dependent kinases (CDKs), particularly CDK2 and CDK4/6, to induce cell cycle arrest in the G1 and G2 phases in response to DNA damage and other cellular stresses (Source: NIH). The promoter region contains multiple binding sites for transcription factors such as p53, Sp1, and MYC, and its activity is heavily regulated by epigenetic mechanisms, including histone acetylation and DNA methylation (Source: NIH, ResearchGate). In many cancers, the CDKN1A promoter is silenced or repressed, facilitating uncontrolled cell growth (Source: PatSnap, MDPI). Therapeutic strategies targeting this promoter include small activating RNAs (saRNAs), such as RAG-01, which utilize RNA activation (RNAa) to specifically induce CDKN1A transcription, as well as histone deacetylase (HDAC) inhibitors like vorinostat that enhance promoter accessibility (Source: PatSnap, MDPI). Beyond its role in oncology, the CDKN1A promoter is involved in cardiomyocyte senescence and heart failure, making it a target of interest for both cancer therapy and regenerative medicine (Source: Frontiers in Cardiovascular Medicine). The promoter's methylation status and histone marks serve as important biomarkers for gene activity and therapeutic response (Source: NIH).

Other names

p21 promoterWAF1 promoterCIP1 promoterCDKN1A regulatory regionp21WAF1/CIP1 promoter

Drugs targeting the CDKN1A promoter primarily act through RNA activation (RNAa) or epigenetic modulation. Small activating RNAs (saRNAs) bind to the promoter sequence to recruit transcriptional machinery and induce p21 expression. Histone deacetylase (HDAC) inhibitors increase histone acetylation at the promoter, promoting an open chromatin configuration and transcriptional activation.